Annals of neurology

MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics.

Greenberg SM, Albert MS, An H, Arfanakis K, Evia AM, Caprihan A, Ford AL, Fornage M, Day GS, Hinman JD, Jicha GA, Kashani AH, Kramer JH, Lachner C, Lee JM, Liu P, Lu H, Maillard P, Petersen RC, Psaty BM, Ringman JM, Rosenberg GA, Satizabal CL, Savitz SI, Schneider JA, Seshadri S, Vemuri P, Wang DJJ, Wilcock DM, Windham BG, Zhang R, Tuozzo C, Singh H, Moy S, Okey-Ewurum V, Page CB, Mulder H, Kivisäkk P, Blacker D, Mazina L, Helmer KG, Schwab K, Wruck LM, Corriveau RA, MarkVCID2 Consortium

Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.

Lagarde J, Maiti P, Schonhaut DR, Blazhenets G, Zhang J, Eloyan A, Thangarajah M, Taurone A, Allen IE, Soleimani-Meigooni DN, Zeltzer E, Windon C, Abu Raya M, Vrillon A, Smith K, Shankar R, Amuiri A, Rocha S, Hammers DB, Dage JL, Nudelman KN, Kirby K, Aisen P, Koeppe R, Landau SM, Carrillo MC, Touroutoglou A, Brickhouse M, Vemuri P, Beckett L, Raman R, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Grant IM, Rogalski E, Johnson ECB, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Dickerson BC, Apostolova LG, La Joie R, Rabinovici GD, LEADS Consortium for the Alzheimer's Disease Neuroimaging Initiative

Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.

Garcia-Cordero I, Anastassiadis C, Khoja A, Morales-Rivero A, Thapa S, Vasilevskaya A, Davenport C, Sumra V, Couto B, Multani N, Taghdiri F, Anor C, Misquitta K, Vandevrede L, Heuer H, Tang-Wai D, Dickerson B, Pantelyat A, Litvan I, Boeve B, Rojas JC, Ljubenkov P, Huey E, Fox S, Kovacs GG, Boxer A, Lang A, Tartaglia MC, 4-R-Tauopathy Neuroimaging Initiative Consortium, and the Alzheimer's Disease Neuroimaging Initiativ